Bridgewater, New Jersey, USA – April 22, 2026

In a transformative move within the global biopharmaceutical landscape, Amneal Pharmaceuticals has announced a definitive agreement to acquire Kashiv BioSciences, positioning itself as a fully integrated global biosimilars leader. The deal, valued at up to $1.1 billion including cash, equity, and milestone-based payments, represents a strategic expansion aimed at capturing a $300 billion+ biologics loss-of-exclusivity (LOE) opportunity expected over the next decade. This acquisition underscores Amneal’s commitment to accelerating growth, enhancing pipeline capabilities, and expanding access to affordable biologic medicines worldwide.

Strategic Expansion into High-Growth Biosimilars Market

The acquisition of Kashiv BioSciences provides Amneal with end-to-end biosimilars capabilities, spanning research, development, manufacturing, and commercialization. Kashiv is recognized for its robust biosimilars pipeline and proven regulatory success, making it a highly complementary addition to Amneal’s existing portfolio.

This strategic combination creates a scaled biosimilars platform capable of delivering multiple product launches annually, significantly enhancing Amneal’s competitive positioning. By 2030, the combined entity is expected to have more than 12 commercial biosimilars and over 20 pipeline candidates, enabling rapid response to the upcoming wave of biologic patent expirations.

The transaction comes at a pivotal moment as biosimilar adoption accelerates globally, driven by the need for cost-effective alternatives to high-priced biologics. With healthcare systems increasingly focused on affordability and access, Amneal’s expanded capabilities position it to lead the next generation of biologic therapies.

Advertisement

cGxPJobs Banner

Financial Strength and Growth Acceleration

The acquisition is structured with $375 million in cash and $375 million in equity at closing, along with additional milestone-based payments and royalties, reflecting a balanced approach to value creation and risk management. The deal is expected to generate $400 million to $500 million in financial synergies, driven by operational efficiencies and elimination of future milestone obligations.

Amneal also reported strong preliminary Q1 2026 financial results, demonstrating solid business momentum. The company achieved $723 million in net revenue, a 4% year-over-year increase, alongside a significant rise in net income and adjusted EBITDA, reflecting improved margins and portfolio performance. Notably, the Specialty segment delivered 23% growth, driven by key product launches and sustained demand.

Based on this strong performance, Amneal has raised its full-year 2026 guidance, projecting adjusted EBITDA of up to $770 million and continued revenue growth. These results highlight the company’s financial resilience and readiness to execute large-scale strategic transactions.

Long-Term Vision and Industry Impact

The acquisition of Kashiv BioSciences represents a major milestone in Amneal’s long-term strategy to diversify its portfolio and strengthen its presence in complex generics, specialty medicines, and biosimilars. By integrating Kashiv’s advanced R&D and manufacturing infrastructure, Amneal aims to accelerate innovation and improve speed-to-market for critical therapies.

This move is expected to significantly expand patient access to high-quality, affordable biologics, particularly in markets where cost remains a barrier to treatment. The combined entity will leverage global scale, operational expertise, and a diversified product pipeline to address evolving healthcare needs.

Pending regulatory and shareholder approvals, the transaction is anticipated to close in the second half of 2026, marking the beginning of a new growth phase for Amneal. As the pharmaceutical industry navigates a period of rapid transformation, this acquisition positions Amneal at the forefront of the biosimilars revolution, enabling it to deliver sustainable growth and long-term value creation.

Source: Amneal, Kashiv BioSciences press release